WDTN Dayton news: FDA approves first melanoma cellular therapy
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, spoke with WDTN Dayton to discuss the approval of Amtagvi, the first cellular therapy for metastatic or unresectable melanoma, a harmful skin cancer.
“It’s actually a cellular therapy but its very different than the cellular therapies that are currently available for a lot of the hematologic malignancies,” said Wise-Draper, a University of Cincinnati Cancer Center member, section head of Medical Oncology and professor in the Division of Hematology/Oncology in UC’s College of Medicine.
The new therapy is for patients who have exhausted all other options.
“Because of the complicated nature of it, not everyone should get the therapy,” Wise-Draper said. “But for those that are fit and able to undergo the multiple treatments, cause it does require a very large multidisciplinary team.”
Wise-Draper said the Cancer Center's team of multidisciplinary experts will evaluate each patient to see if they are a fit for Amtagvi, since it is extensive.
“It’s really important that we evaluate the patient for feasibility upfront,” she said, “and make sure that’s something they’ll be able to undergo.”
Featured photo at top of Wise-Draper, left, and Vinita Takiar in their research laboratory. Photo/Colleen Kelley/UC Marketing + Brand
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.